Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

计划入组 293 人 · 首次发布于 2008 年 1 月 28 日

ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)

计划入组 45 人 · 首次发布于 2026 年 4 月 20 日

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

计划入组 370 人 · 首次发布于 2023 年 12 月 28 日

Tamoxifen(Soltamox)

C₂₆H₂₉NO · Rx

Raloxifene(Evista, Optruma, Raloxifene Teva)

C₂₈H₂₇NO₄S · Rx

Aprotinin(Artiss, Tisseel, Trasylol)

ADVANTAGE RISK MANAGEMENT CO., LTD.

Japan

TWG HEALTH RISK MANAGEMENT (PTY) LTD

South Africa

NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH

United States

Clairity, Myriad Genetics, and MagView Launch First Integrated AI-Genetic Risk Platform for Breast Cancer Screening

Laura J. van 't Veer Honored with 2024 William L. McGuire Memorial Lecture Award for Breast Cancer Advancements

Personalised, risk-adapted therapy doubles six-year survival in high-risk multiple myeloma